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Purpose:  In  April  2007,  Panama  introduced  Hepatitis  A universal  vaccination  using  a  two-dose  schedule
(Havrix® junior;  GSK  Vaccines,  Belgium).  We  assessed  the impact  of  this  hepatitis  A vaccine  three  years
after  it was  recommended  for universal  mass  vaccination  in  Panama.
Materials  and methods:  Hepatitis  A vaccination  impact  was  assessed  using  two  different  approaches.  The
ﬁrst approach  used  retrospective  data  (incidence  and  number  of  cases  for  all age  groups),  collected  from
the passive  surveillance  of the  Epidemiologic  Surveillance  System  of  the  Ministry  of Health  of  hepatitis  A
and  unspeciﬁed  hepatitis  before  (2000–2006)  and  after  (2008–2010)  introduction  of  hepatitis  A  vaccine.
The  second  approach  was a prospective  hospital-based  active  surveillance  for hepatitis  cases  conducted
in  subjects  (0–14years)  during  2009–2011  at three  sentinel  hospitals  in Panama.
Results:  Overall,  the  annual  incidence  of  hepatitis  A  and  unspeciﬁed  hepatitis  in 2008,  2009  and  2010  were
13.1,  7.9  and  3.7  per  100,000  subjects,  lower  than  the baseline  incidence  of  51.1  per 100,000  subjects.  In
comparison  to the  mean  baseline  period  (2000–2006),  there  was  an  82%  mean  reduction  in the  overall
hepatitis-related  outcomes  (hepatitis  A and  unspeciﬁed  hepatitis)  after  vaccine  introduction  (2008–2010)
in  all  age  groups.
In  the hospital-based  surveillance  (2009–2011),  of the  42  probable  viral  hepatitis  A  cases,  nine  cases
were  conﬁrmed  as acute  hepatitis  A (8 in 2009,  1 in  2010).  Of these  conﬁrmed  cases,  two  belonged  to the
targeted  vaccine  group  (1–4 years)  but were  not  vaccinated.
Conclusions:  Our  study  suggests  that  the introduction  of  two-dose  hepatitis  A  vaccines  in Panama  has
contributed  to the reduction  in  the  incidence  of overall  hepatitis-related  outcomes  for all  age  groups,
suggesting  herd  protection.  Additional  monitoring  is required  to document  a sustained  long-term  effect.
© 2015  The  Authors.  Publis
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase;
I, conﬁdence interval; HAV, hepatitis A vaccine; HDN, Hospital Del Nin˜o; HEP, Hos-
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1. Introduction
Hepatitis A (HepA) is one of the most common forms of acute
viral liver infection and results in approximately 1.5 million clin-
ical cases annually worldwide [1–3]. This self-limiting disease
accounted for 34,000 deaths globally in 2005 [4] but was three
times higher in 2010, when 102,000 deaths occurred [5]. HepA was
reported to be highly endemic in regions such as South and Central
America, the Middle East, South-East Asia and Africa [6,7]. How-
ever, a shift in the endemicity towards intermediate was observed
in many regions including Asia, Latin America, Eastern Europe
and Middle East [7,8]. This shift may increase the probability of
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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cquiring HepA infection in older susceptible individuals, which
ay  lead to outbreaks and higher severity; therefore, the World
ealth Organisation (WHO) recommends widespread vaccination
6–9].
The inactivated hepatitis A vaccines (HAV); Havrix® (GSK Vac-
ines, Belgium) and Vaqta® (Merck) are licensed in Europe and the
nited States, Epaxal® (Crucell) in Switzerland and Argentina and
ealive is licensed in China [6,10]. Havrix® (1440 ELISA units per
illilitre [ml] suspension) and Havrix® junior (720 ELISA units in
.5 ml  suspension) are two variants of the same vaccine with vary-
ng viral antigen content. Havrix® junior is a two-dose inactivated
accine that was implemented for the ﬁrst time in Latin America in
007 and administered to children in Panama since then, through a
niversal Mass Vaccination (UMV) programme [11]. The ﬁrst dose
s recommended between 12–18 months of age and the second
ose, 6–12 months after the ﬁrst dose [11]. Previous studies sug-
est that national immunization programmes with one or two-dose
accination schedules resulted in reduction of HepA rates [12–17].
Our aim was to assess the impact of HAV when given as a two-
ose schedule. Further, we assessed the trend in the incidence
nd frequency of HepA cases over time to describe the charac-
eristics and clinical outcomes of acute hepatitis cases during the
ost-vaccination period.
. Methods
Assessment of vaccine impact in terms of reduction in the
epA burden of disease was conducted using two different
ethodologies. The ﬁrst method (time-trend analysis) employed
 passive surveillance system using the retrospective national hos-
ital admission data to assess the direct and indirect impact of
epA vaccination over a 10-year period (2000–2010), including the
mpact of the vaccine in different regions. The second methodology
descriptive analysis) was an active hospital-based surveillance for
rospective data collection on the occurrence of conﬁrmed cases
f acute HepA cases during the post-vaccine introduction period
2009–2011). Both methods were used to describe the vaccine
mpact in various age groups (ﬁrst method: all age groups; second
ethod: <15years).
.1. Time-trend analysis
The national Epidemiologic Surveillance System of the Ministry
f Health (MoH) databases indicated that HepA and unspeciﬁed
epatitis are notiﬁable diseases in Panama [18]. Reported number
f HepA and unspeciﬁed hepatitis cases was collected using this
atabase. It was considered that most of the unspeciﬁed hepatitis
ases would correspond to HepA cases. A systematic analysis was
erformed on Panamanian population data (characterised by year,
ge and region) during 2000–2010. Aggregated data for HepA and
nspeciﬁed hepatitis with vaccine dose information were analysed
or three time periods; baseline period (2000–2006), transition year
2007) and post-vaccine introduction period (2008–2010).
Serological analysis is usually done to conﬁrm HepA cases as
er local algorithm. However, unconﬁrmed cases were reported as
nspeciﬁed hepatitis which corresponds to an acute liver inﬂam-
ation, mostly caused by HepA virus infection characterized by
estruction of liver cells and presence of inﬂammatory cells in liver
issue. These outcomes were extracted using the International Clas-
iﬁcation of Diseases (ICD) codes; ICD 10 code B15.9 and ICD 9 code
70.1 was used to denote ‘hepatitis A without hepatic coma’ and
CD 10 code B19.9 and ICD 9 code 070.9 was assigned to ‘unspeciﬁed
epatitis without hepatic coma’, as reference [19,20].
For incidence estimations, we collected data on population by
ge group, year and region from the Directorate of Statistics and33 (2015) 3200–3207 3201
Census of the National Controller Ofﬁce (Contraloría General de
la República) [21]. Data were grouped by region (West, Central,
Panama and North-East) and age (<1 year, 1–4 years, 5–9 years,
10–14 years, 15–19 years, 20–24 years, 25–49 years and ≥50 years)
and year of the study. No exclusion criteria were applied for the
time-trend analysis.
Vaccine dose information was  provided by the Expanded Pro-
gramme  on Immunization for years from 2007 to 2010 and vaccine
coverage was  calculated at six months interval. Partial vaccine
coverage population included subjects who had received at least
one vaccine dose and the complete vaccine coverage population
included those who  had received both vaccine doses. Denominator
data for vaccine coverage per study year were derived from children
who aged less than one year in the previous year.
The outcome of the time-trend analysis was the occurrence of
hepatitis-related outcomes in the post-vaccine introduction period
(2008–2010) as compared with the baseline period (2000–2006)
and the incidence of hepatitis-related outcomes by year, age and
region. The annual incidence of hepatitis-related outcomes was cal-
culated per 100,000 subjects with 95% conﬁdence intervals (CI).
Year-wise comparisons were made between the mean and median
for number of cases and incidences for baseline and the post-
vaccine introduction period.
Negative binomial regression (NBR) model was used to com-
pare trends in the number and incidence of hepatitis-related
outcomes under study to assess vaccination impact [22,23]. To
account for the actual vaccination impact, the already existing trend
of reduced HepA cases was  compared with the expected trends
derived from the NBR model. The covariates included for this math-
ematical model were year, age group, region and vaccination period
(baseline period = 0, transition period = 1 and post-vaccination
period = 2). p Values were calculated for the regression coefﬁcients
(or rate of change) in the hepatitis-related outcomes and values
less than 0.05 were considered signiﬁcant. The same model was
also used to predict number of cases and incidence of hepatitis-
related outcomes in a hypothetical situation, where the HAV was
not included in UMV.
2.2. Hospital-based surveillance
The hospital-based active surveillance was conducted between
July 2009 and October 2011 at two hospitals located in Panama
City (Hospital Del Nin˜o [HDN] and Hospital de Especialidades Pedi-
atricas [HEP]) and one hospital (Hospital Integrado San Miguel
Arcangel [HISMA]) located in the neighbourhood of San Miguelito
found on the outskirts of Panama City. These hospitals had a total
catchment population of over one million, derived from Panama
City neighbourhoods where the majority of HepA cases were
reported. This surveillance aimed to validate the reported outcomes
from the passive reporting system.
Children with clinical diagnosis of possible acute HepA (children
between >1 month and <15 years of age who attended one of the
designated hospitals for an acute disease characterized by discrete
onset of symptoms [dark urine, anorexia, malaise, extreme fatigue
and abdominal pain] and jaundice) were eligible for study inclu-
sion. Potential participants with conﬁrmed diagnosis of non-viral
hepatitis were excluded.
Blood samples were collected from all enrolled subjects and
serum was  tested for transaminase levels. Serological diagnosis
was done at the hospital laboratory where each participant was
enrolled.
A probable case of HepA was  deﬁned as a possible HepA
case with a serum aspartate aminotransferase [AST] and alanine
aminotransferase [ALT]) level 2.5-times higher than the maximum
limit of normal range for the laboratory of each hospital (HDN:
ALT = 11–66 units/litre [U/L], AST = 15–46 U/L; HEP: ALT = 7–56 U/L,
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ST = 5–40 U/L and HISMA: ALT = 21–72 [boys], 9–52 U/L [girls],
ST = 17–59 U/L [boys], 14–36 U/L [girls]).
A conﬁrmed acute HepA case was deﬁned as a probable case
f acute HepA presenting a positive result for immunoglobulin M
IgM) for HepA virus. All probable HepA cases were assessed for
cute HepA infection using microparticle enzyme immunoassay
MEIA) to detect the presence of anti-HepA virus IgM antibodies.
EIA was performed in a private central laboratory. An index value
1.20 indicated a positive test result; an index value <0.80 indi-
ated a negative test and values between 0.80 and 1.20 indicated
n indeterminate result. A new serum sample was tested when the
rst sample resulted in an indeterminate result.
The occurrence of conﬁrmed acute HepA cases and percentage
f IgM anti-HepA virus positive cases were analysed by year, age
roup and vaccination status for the hospital-based surveillance
opulation.
All statistical analyses for both methodologies were performed
sing Statistical Analysis System (SAS) Version 9.2.
.3. Ethical aspects
The studies were conducted in accordance with the Interna-
ional Conference on Harmonisation guideline for Good Clinical
ractice, the Declaration of Helsinki and local rules and regulations.
he studies also complied with the International Guidelines for eth-
cal review of epidemiological studies. For the subjects included
n the hospital-based surveillance, written informed consent was
btained from a parent/guardian before the study started. The pro-
ocol and other documents associated with both the methodologies
ere reviewed and approved by the Institutional Review Board and
ndependent Ethics Committee of Panama.
. Results
.1. Epidemiologic surveillance system databases and time trend
nalyses
Between 2000 and 2010, a total of 12,665 viral hepatitis cases
HepA = 2587; unspeciﬁed hepatitis = 10,078) were recorded. In
000, there were 2769 cases (96.9 per 100,000 subjects) which
educed to 941 cases (28.7 per 100,000 subjects) by 2006. An addi-
ional reduction in cases was also observed during 2008 (446 cases
13.1 per 100,000 subjects]), 2009 (271 cases [7.9 per 100,000
ubjects]) and 2010 (130 cases [3.7 per 100,000 subjects]) in com-
arison to the baseline mean incidence of 51.1 per 100,000 subjects.
Mean number (±Standard Deviation [SD]) of viral hepatitis
ases during the baseline period (2000–2006) and post-vaccination
eriod (2008–2010) were 1565 (±588) and 282.3 (±158), respec-
ively. Compared to the baseline mean, there was an overall mean
eduction of 82% and among all 4 regions, highest reduction (85%)
as observed in Panama. The occurrence of HepA cases and unspec-
ﬁed hepatitis cases also gradually reduced (Fig. 1).
Reduction in the incidence of hepatitis-related outcomes was
lso observed among all age groups during the post-vaccination
eriod (Fig. 2, Supplementary Table 1). In Panama the incidence
f viral hepatitis also reduced during the post-vaccination period:
008 (11.0 per 100,000 subjects), 2009 (11.1 per 100,000 subjects)
nd 2010 (3.1 per 100,000 subjects).
A 90% reduction in hepatitis A incidence in the vaccinated pop-
lation was noted, and 87% in the general population.
The observed viral hepatitis-related outcome (38.1% in 2008;
6.5% in 2009; 75.8% in 2010) was lower than expected during
ost-vaccination period (Fig. 3). Using this model, an additional
mpact of vaccination after 2007 was also conﬁrmed when the over-
ll viral hepatitis incidence was observed to be 3.7 per 100,00033 (2015) 3200–3207
in 2010 instead of the expected incidence of 14.6 per 100,000
(Fig. 4). A signiﬁcant reduction (58%; p < 0.0001) in the incidence of
overall hepatitis-related outcome was  also observed (after adjus-
ting for year, age and region effect) during 2008–2010 as compared
with baseline period (2000–2006). A decline in incidence of HepA
cases by 52% (p = 0.0054) and unspeciﬁed hepatitis cases by 62%
(p < 0.0001) was  observed in post-vaccination period compared to
baseline period (Table 1). During 2000–2010, a signiﬁcant decline
(p < 0.01) in the occurrence of overall viral hepatitis-related out-
come was observed in subjects aged <1 year and ≥20 years as
compared to the subjects aged 1–4 years (targeted vaccine age
group).
Between 2007 and 2010, 241,288 ﬁrst and 129,720 second doses
of HAV were administered in Panama via the Expanded Program
on Immunisation. Vaccine coverage among subjects who  received
partial vaccination was minimum in 2010 (70.7%) and maximum
(99.8%) in 2008. The vaccine coverage of 66.4% was observed in
subjects who received complete vaccination in 2009 (Fig. 1).
3.2. Hospital-based surveillance
During the hospital-based surveillance, 42 subjects (15 subjects
in 2009, 17 subjects in 2010 and 10 subjects in 2011) with pos-
sible HepA were enrolled. Mean age of the enrolled subjects was
5.81 years (SD ± 4.49 years). The study population included equal
number of boys and girls. All subjects reported AST and ALT levels
above the maximum reference range corresponding to probable
cases. Most subjects (95.2%; 40/42) visited two  hospitals located in
Panama City (HDN and HEP).
Nine subjects (21.4%) were subsequently conﬁrmed as having
acute HepA: eight occurred in 15 probable cases in 2009 (53.3%) and
one occurred in 17 probable cases in 2010 (5.9%). Of 10 probable
acute HepA cases, no conﬁrmed acute HepA cases occurred in 2011.
Of the nine conﬁrmed cases, eight were not vaccinated with HAV
and one had unknown vaccination status.
The highest number of conﬁrmed acute HepA cases was
reported in subjects aged 5–9 years (40% [95% CI: 12.2–73.8] in
2009); followed by subjects aged 10–14 years (27.3% [95% CI:
6.0–61.0] in 2009). There were two conﬁrmed cases in subjects aged
1–4 years (1 each in 2009 and 2010) who  were not vaccinated with
HAV.
4. Discussion
HepA virus infection and the prevalence of anti-HepA virus
antibodies are strongly inﬂuenced by the economic and sanitary
condition of the region [5,7,24]. Improved sanitation and accessible
safe drinking water decreases child morbidity and mortality rates,
increases the mean age of infection [4,5,24], thereby increasing the
risk of getting infected later in life [24]. This has been evidenced by
the endemicity shift of HepA as per recent reports in Latin American
countries [9,24,25]. Hence, the strategy to introduce HepA vaccina-
tion into the UMV  in Panama was  warranted.
WHO  recommends a two-dose inactivated HAV that should be
given at age ≥1 year [26]. Some countries may consider a single
dose schedule as it is believed to show high immune response
[14]. However, two-dose HAV is still preferred for immunocompro-
mised individuals and those at substantial risk of contracting HepA
[26] as evidenced in Israel [16]. Both long-term [27,28] and model-
based studies [29,30] suggested a two-dose HAV induced antibody
persistence for at least 15 and 40 years after primary vaccination,
respectively. There are also reports of long-term persistence of 17
years with a three-dose vaccination schedule showing protective
HAV antibody levels [31]. Additionally, WHO  recommends that the
Strategic Advisory Group of Experts (SAGE) Hepatitis A Working
D. Estripeaut et al. / Vaccine 33 (2015) 3200–3207 3203
Fig. 1. Reduction of viral hepatitis (hepatitis A and unspeciﬁed hepatitis combined) cases and vaccine coverage among subjects who  received two vaccine doses. West region
included: Bocas del Toro, Chiriqui, Ngöbe Buglé; Central region included—Coclé, Herrera, Los Santos, Veraguas; Panama region included—Panamá Este, Panamá Oeste, Panamá
Metro,  San Miguelito; Northeast region included—Colón, Darién, Kuna Yala; Baseline = mean of pre-vaccination period from 2000 to 2006; 2007 was the ‘transition year’ of
vaccine introduction; Post-vaccination period = mean of post-vaccination period from 2008–2010; The arrows indicate the difference in reduction of the number of cases in
the  post-vaccination period compared to the baseline period; Full vaccination: for the subjects who received full vaccination (both the doses of Hepatitis A vaccine); Partial
vaccination: for the subjects who received partial vaccination (at least one dose of Hepatitis A vaccine).
Fig. 2. Trends over time for the incidence of viral hepatitis-related outcome by age. 2000–2010: study period; 2000–2006: baseline period; 2007: year of vaccine introduction;
2008–2010: post-vaccination period.
3204 D. Estripeaut et al. / Vaccine 33 (2015) 3200–3207
Fig. 3. Trend over time for the occurrence of hepatitis-related outcome by observed versus expected number of cases. (A) Trend over time for overall occurrence of viral
hepatitis (hepatitis A and unspeciﬁed hepatitis) related outcome by observed versus expected number of cases; (B) Trend over time for occurrence of hepatitis A outcome
by  observed versus expected number of cases (C) trend over time for occurrence of unspeciﬁed viral hepatitis outcome by observed versus expected number of cases.
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roup should continue monitoring the long-term protection and
AV impact either used in single or two-dose schedules [32].
The impact of two-dose schedule of HAV was evaluated for
he ﬁrst time in Panama after three years of vaccine introduction
hich was in line with the WHO  recommendation. Our results
able 1
ummary of negative binomial regression model for incidence of viral hepatitis-related o
Outcome
type
Independent
variables
e(ß)
Hepatitis A Year 0.97 
Post-vaccination vs pre-vaccination 0.48 
Unspeciﬁed
hepatitis
Year 0.86 
Post-vaccination vs pre-vaccination 0.38 
Overall Year 0.87 
Post-vaccination vs pre-vaccination 0.42 
(ß): Exponentiated regression coefﬁcients {i.e. exp(ß)}. p-Value: Probability value at alph
omes)  = log (population at risk) + Intercept + (coefﬁcient × year) + (coefﬁcient × age group
ariable where pre-vaccination (2000–2006) = 0, Transition (2007) = 1 and Post vaccinatio
able.
Rate of change is calculated by (e(ß) − 1) × 100%.
5% CI of e(ß): Lower and upper limit for the two  sided 95% conﬁdence interval of exp(ß): post-vaccination period. Negative binomial regression model: log (no. of hepatitis
 predict the cases from year 2000–2010 using the baseline period.
showed a decline in the number of hepatitis-related outcomes in
Panama over time (2000–2010).Though a decreasing trend was
observed, supporting the major sanitary improvements in early
2000’s reported by the Ministry of Health, Panama [33], a greater
decline in the incidence of HepA cases after 2007 was noted.
utcome.
p value Rate of
change*
95% CI
LL UL
0.4180 −3.07 0.90 1.05
0.0054 −52.48 0.28 0.80
<0.0001 −14.36 0.82 0.90
<0.0001 −62.20 0.27 0.53
<0.0001 −12.77 0.84 0.91
<0.0001 −58.01 0.31 0.57
a = 0.05 level. Negative binomial regression model: log (No. of Hepatitis related out-
) + (coefﬁcient × regions) + (coefﬁcient × vaccination). Note: vaccination is dummy
n (2008–2010) = 2. The result related to age group and region is not provided in this
.
D. Estripeaut et al. / Vaccine 33 (2015) 3200–3207 3205
Fig. 4. Impact of vaccination and natural reduction in incidence over time for hepatitis-related outcome. (A) Trend over time for overall viral hepatitis (hepatitis A and
unspeciﬁed hepatitis) related outcome by observed versus expected incidence; (B) Trend over time for hepatitis A outcome by observed versus expected incidence; (C) Trend
over  time for unspeciﬁed viral hepatitis outcome by observed versus expected incidence. 2000–2010: study period; 2000–2006: baseline period; 2007: transition year;
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herefore, we  believe reduction during the post-vaccination period
as due to the vaccine’s effect. NBR model showed that the
bserved viral hepatitis cases were substantially lower than the
xpected cases, thereby demonstrating vaccination impact. Dur-
ng outbreaks, most cases (≈90%) were laboratory-conﬁrmed HepA
ases compared to cases (≈10%) during post-vaccination period.
ifferences between number of HepA and unspeciﬁed hepatitis
ases might be attributed to differences in surveillance procedures
uring outbreaks. Both surveillance procedures suggest a direct
accine impact on the incidence of HepA cases in the targeted vac-
ine group. After vaccine introduction, similar reductions in the rate
f acute HepA cases have been observed in the United States (1.0 to
.4 cases per 100,000 subjects) during 2007–2011 [34], Argentina
single-dose HAV) (85.5 per 100,000 subjects in 1998–2002 to 10.2
er 100,000 subjects in 2007) [35] and Israel (50.4 per 100,000
ubjects in 1993–1998 to 2.5 per 100,000 in 2004) [15,16].
Although in 2010, the vaccine coverage for the ﬁrst dose was
1% and only 40% for complete vaccination due to vaccine sup-
ly issues in Panama. However, our surveillance reports indicated 91.7% reduction in hepatitis-related outcomes in all age groups
including adolescents and elderly) compared to the baseline mean
uggesting a possible high degree of vaccine-induced herd pro-
ection. Following HepA immunization of toddlers in the Unitede incidence rates from year 2000–2010 based on baseline period from 2000–2006
ﬁed hepatitis outcomes) = log (population at risk) + Intercept + (coefﬁcient × year);
States, a reduced number of outbreaks was observed [36]. After
the implementation of routine HepA vaccination across 17 states
in the United States, despite low vaccine coverage (25% to 50%), a
large decrease in the incidence of HepA cases was observed [37–39].
Israel experienced a remarkable decrease in the number of HepA
cases during 2001–2005 by employing routine HepA vaccination
among toddlers [12,16]. Although a lesser proportion of Israeli chil-
dren received the complete HepA vaccination course (77% vaccine
coverage), marked herd protection among children up to 3 years of
age was observed [12].
Additionally, there was  a smaller difference in ﬁrst and second
dose vaccine coverage during the ﬁrst year than the second year.
Thus, conﬁrming a substantial reduction in HepA transmission rates
even with low coverage, supporting the fact that HAV offers pro-
tection against infection and viral excretion, also seen in animal
models [38].
Our studies had some limitations. For the trend analysis, data
used from passive surveillance system for the retrospective time-
trend analysis might be an underestimation of disease burden.
The underestimation could be due to lack of speciﬁcity in labora-
tory tests used for conﬁrmed HepA cases. Regarding hospital-based
surveillance; conducted in only three sentinel reference hospitals
might not completely represent the diversity of socio-economic
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onditions in Panama. To overcome these limitations, future stud-
es might be necessary including primary care facilities around the
entinel hospitals.
Strengths include the combination of retrospective time-trend
nalyses and active hospital-based surveillance to document the
accination impact which made our results robust. Furthermore,
ctive surveillance was performed at sentinel hospitals post-
accine introduction that was reconciled with passive surveillance
o detect any potential under-reporting in the surveillance system.
s a result, no under-reporting was noted.
Our study suggested that the introduction of a two-dose HAV has
ontributed to the reduction in the overall incidence of hepatitis-
elated outcomes in Panama. Impact of HAV in all age groups in
oth the settings suggested herd protection in the early phases of
he vaccine implementation. Additional monitoring is required to
ocument a sustained long-term effect of the vaccine.
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